Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel, Sequential Consolidation With Nab-paclitaxel Followed by Pembrolizumab and Concurrent Consolidation With Nab-paclitaxel and Pembrolizumab After Standard First-Line Induction Chemotherapy in Advanced NSCLC
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Mar 2017 Planned End Date changed from 1 Aug 2019 to 1 Feb 2023.
- 10 Mar 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Feb 2023.
- 19 Sep 2016 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.